[Evaluation of the clinico-metabolic effects of administration of an association of rauwolfia, vasoactive drugs and hydroflumethiazide in a group of hypertensive patients].
D000959:Antihypertensive Agents / Q000627:therapeutic use; D006801:Humans; D006857:Hydroflumethiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D007294:Inositol / Q000627:therapeutic use*; D008517:Phytotherapy; D010946:Plants, Medicinal; D011926:Rauwolfia / Q000627:therapeutic use*; D012110:Reserpine / Q000627:therapeutic use*; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use*; D013805:Theobromine / Q000627:therapeutic use*; D015016:Yohimbine / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine; D007294:Inositol; D006857:Hydroflumethiazide; D012110:Reserpine; D013805:Theobromine
Valutazione degli effetti clinico-metabolici conseguenti alla somministrazione di una associazione rauwolfia-vasoattivi-idroeflumetiazide in un gruppo di pazienti ipertesi.